Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Court: No Herceptin Biosimilar Tag For Indian Trastuzumabs

Executive Summary

An Indian court appears to have delivered a frontal blow to defendants Biocon and Mylan in a hotly contested case concerning their biosimilar versions of Roche's Herceptin (trastuzumab).


Related Content

Roche Faces Probe On Claims It Derailed Biosimilar Herceptin
Indian Herceptin Biosimilars Case Simmers
Roche Blocks Indian Trastuzumab; Says No Room For ''Uncertainty''
Relief And Rebuke For Biocon In Herceptin Biosimilars Case
Mylan confident on biosim Herceptin in India despite Roche tactics





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts